Related by context. Frequent words. (Click for all words.) 83 Clinical Trial Results 82 Drug Candidate 82 Phase III Trial 81 FDA Accepts 80 Phase III Clinical Trial 80 Patient Enrollment 80 Pivotal Phase III 80 Well Tolerated 80 Presents Positive 79 Completes Enrollment 78 Generic Version 78 Preclinical Data 78 Cholesterol Drug 77 Extended Release 76 Blood Thinner 76 FDA Clears 76 Low Dose 76 FDA Approves 76 Positive Opinion 76 Pivotal Phase 75 Pivotal Trial 75 Study Demonstrates 75 Chronic Hepatitis C 75 Patients Treated 75 Combination Therapy 75 Overactive Bladder 74 Monotherapy 74 Aliskiren 74 Pulmonary Arterial Hypertension 74 Elderly Patients 74 Prostate Cancer Patients 74 Postmenopausal Women 73 Benign Prostatic Hyperplasia 73 Monoclonal Antibody 73 Metastatic Melanoma 73 Metastatic Colorectal Cancer 73 Advanced Prostate Cancer 73 Tolerability 73 Boceprevir 73 Significantly Reduces 72 Patent Covering 72 Small Molecule 72 Cardiovascular Events 72 RNAi Therapeutics 72 Dasatinib 72 Initiates Phase 72 Enoxaparin 72 Venous Thromboembolism 72 Cethromycin 72 Inhibits 72 Hormone Therapy 72 Shows Promise 72 Extended Release Tablets 72 Allergic Rhinitis 72 Heart Failure Patients 72 Atopic Dermatitis 71 Meta Analysis 71 Receives FDA Clearance 71 Rivaroxaban 71 Diet Pill 71 Announces Publication 71 Reduces Risk 71 Drug Resistant 71 Breast Cancer Treatment 70 Bevacizumab 70 Diabetic Patients 70 Prostate Cancer Treatment 70 Cervical Cancer Vaccine 70 Laquinimod 70 Gemcitabine 70 Etanercept 70 Increases Risk 70 Eltrombopag 70 Capecitabine 70 Epratuzumab 70 Chronic Lymphocytic Leukemia 70 Announces Presentation 70 Pirfenidone 70 Breast Cancer Patients 70 Smallpox Vaccine 69 Increased Risk 69 Panzem R 69 Induces 69 Nasal Spray 69 Announces Initiation 69 FDA Clearance 69 Antihypertensive 69 Inc Therapeutic Competitors 69 Adalimumab 69 Clinical Study 69 J Am Coll 69 Study Indicates 69 Study Confirms 69 Erlotinib 69 Cancer Treatments 68 Insulin Resistance 68 Hepatitis C Virus 68 Pravastatin 68 FDA Warns 68 Autoimmune Diseases 68 Ofatumumab